Compare Biogen Inc (BIIB) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Domino's Pizza, Inc. — how do they compare? Biogen Inc trades at $205.49 (market cap $30.13B), while Domino's Pizza, Inc. trades at $353.5 (market cap $11.82B). The key difference: Biogen Inc is far larger — about 2.5× Domino's Pizza, Inc.'s market cap, and Domino's Pizza, Inc. pays a 2.23% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | DPZ | |
|---|---|---|
Market Cap | $30.13B | $11.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $467.30 |
52-Week Low | $128.93 | $282.89 |
Enterprise Value | $37.20B | $16.78B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Domino's Pizza (DPZ) trades at $347.85, down 0.88% on the day, with mixed technical signals showing neutral overall momentum. The company reported three consecutive quarterly EPS misses but maintains strong profitability with 11.86% net margins and positive revenue growth. Recent news highlights product innovation with the launch of individual-sized pizzas and digital platform enhancements to drive customer engagement.
Wall Street maintains a bullish stance with 54% buy ratings and a $371.67 price target, representing 7% upside potential. Key risks include elevated debt levels, competitive pressures, and consumer spending sensitivity. The stock offers value through consistent dividends and operational efficiency, though near-term execution on sales growth remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
